Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclonal antibody in relapsed/refractory B‐cell non‐Hodgkin lymphoma.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 7, p. 1281, doi. 10.1002/ajh.27341
- By:
- Publication type:
- Article
Works by Musick, Lisa
Results: 2
1
2
Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: A phase III bridging study in Chinese patients.
- Published in:
- Journal of Cancer Research & Therapeutics, 2024, v. 20, n. 7, p. 2133, doi. 10.4103/jcrt.jcrt_269_24
- By:
- Publication type:
- Article